Markers and mediators of inflammation in neonatal lung disease

Pediatric Pulmonology

Volumn 23, Issue 4, 1997, Pages 292-306

  Özdemir, Ali ^a   Brown, Mark A ^a,b   Morgan, Wayne J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

bronchopulmonary dysplasia; cytokines; neonatal lung inflammation

Indexed keywords

6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CATALASE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; DEXAMETHASONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 8; PROTIRELIN; RECOMBINANT PROTEIN; RETINOL; SALBUTAMOL; SUPEROXIDE DISMUTASE; SURFACTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFANT; INFLAMMATORY DISEASE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; NEWBORN DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BRONCHOPULMONARY DYSPLASIA; CYTOKINES; HUMANS; INFANT, NEWBORN; INFLAMMATION; LUNG;

EID: 0030968060     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199704)23:4<292::AID-PPUL7>3.0.CO;2-O     Document Type: Review

References (153)

1. Frank L. Antioxidants, nutrition and bronchopulmonary dysplasia. Clin Perinatol. 1992; 19:541-562.
2. Davis JM, Rosenfeld WN. Chronic lung disease. In: Avery GB, Fletcher MA, MacDonald MG, eds. Neonatalogy: Pathophysiology and Management of the Newborn. Philadelphia: J.B. Lippincott, 1994:453-477.
3. Southall DP, Samuels MP. Bronchopulmonary dysplasia: A new look at management. Arch Dis Child. 1990; 65:1089-1095.
4. Rush MG, Hazinski TA. Current therapy of bronchopulmonary dysplasia. Clin Perinatol. 1992; 19:563-590.
5. Aggarwal BB, Puri RK. Common and uncommon features of cytokines and cytokine receptors: An overview. In: Aggarwal BB, Puri RK, eds. Human Cytokines: Their Role in Disease and Therapy. Ann Arbor: Blackwell Science, 1995:3-24.
6. Hempel SL, Monick MM, Hunninghake GW. Effect of hypoxia on release of IL-1 and TNF by human alveolar macrophages. Am J Respir Cell Mol Biol. 1996; 14:170-176.
7. Koga S, Ogawa S, Kuwabara K, Brett J, Leavy JA, Ryan J, Koga Y, Plocinski J, Benjamin W, Burns DK, Stern D. Synthesis and release of interleukin-1 by neoxygenated human mononuclear phagocytes. J Clin Invest. 1992; 90:1007-1015.
8. Yuan HT, Bingle CD, Kelly FJ. Hyperoxia-induced pulmonary antioxidant enzyme (AOE) and cytokine mRNA induction in premature guinea pigs (Abstract). Am J Respir Crit Care Med. 1996; 153:635A.
9. Vilček J, Le J. Immunology of cytokines: An introduction. In: Thomson A, ed. The Cytokine Handbook. San Diego: Academic Press, 1994:1-19.
10. Whicher JT, Evans SW. Cytokines in disease. Clin Chem. 1990; 36:1269-1281.
11. Dinarello CA. Interleukin-1. In: Thomson A, ed. The Cytokine Handbook. San Diego: Academic Press, 1994:31-36.
12. Burger D, Dayer JM. Inhibitory cytokines and cytokine inhibitors? Neurology. 1995; 45:S39-S43.
13. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax. 1993; 48:931-935.
14. Clancy RM, Dahinden CA, Hughi TE. Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by human N-formyl-met-leu-phe or complement component C5a is independent of phospholipase activation. Proc Natl Acad Sci USA. 1983; 80:7200-7204.
15. Lewis RA, Austen KF. The biologically active leukotrienes biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest. 1984; 73:889-897.
16. 4, and platelet-activating factor on neutrophil chemotaxis of the newborn. Pediatr Res. 1995; 38:11-16.
17. 4 biosynthesis. J Invest Dermatol. 1991; 96:260-266.
18. 4 by human neutrophil in response to platelet-activating factor. J Immunol. 1991; 146:1204-1211.
19. Warren JS. Relationship between interleukin-1 beta and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat. Am J Pathol. 1992; 141:551-560.
20. Bolognesi M, Djinovic-Carugo K, Ascenzi P. Molecular bases for human leucocyte elastase inhibition. Monaldi Arch Chest Dis. 1994; 49:144-149.
21. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of anti-leukoprotease and lysozyme in humans. J Histochem Cytochem. 1989; 37:493-498.
22. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 1986; 83:6692-6696.
23. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The introduction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis. 1977; 116:469-475.
24. Lee CT, Fein AM, Lippmann M, Holtzman H, Kimbel P, Weinbaum G. Elastolytic activity of pulmonary lavage fluid from patients with adult respiratory distress syndrome. N Engl J Med. 1981; 304:192-196.
25. Powers JC, Bengali ZH. Elastase inhibitors for treatment of emphysema: Approaches to synthesis and biochemical evaluation. Am Rev Respir Dis. 1986; 134:1097-1100.
26. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Neutrophil elastase increased secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol. 1993; 265:L286-L292.
27. Polin RA. Role of fibronectin in diseases of newborn infants and children. Rev Infect Dis. 1990; 12:S428-S438.
28. Mosher DF. Physiology of fibronectin. Annu Rev Med. 1984; 35:561-575.
29. Brandes ME, Finkelstein JN. The production of alveolar macrophage-derived growth-regulating proteins in response to lung injury. Toxicol Lett. 1990; 54:3-22.
30. Watts CL, Fanaroff AA, Bruce MC. Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr. 1992; 120:614-620.
31. Strieter RM, Kunkel SL. Acute lung injury: The role of cytokines in the elicitation of neutrophils. J Invest Med. 1994; 42:640-651.
32. Liles WC, Van Voorhis WC. Review: Nomenclature and biologic significance of cytokines involved in inflammation and host immune response. J Infect Dis. 1995; 172:1573-1580.
33. Yoder MC. Development of respiratory defences. In: Loughlin GM, Eigen H, eds. Respiratory Disease in Children: Diagnosis and Management. Baltimore: Williams & Wilkins. 1994:35-45.
34. Bellanti JA, Pong YH, Zeligs BJ. Immunology. In: Avery GB, Fletcher MA, MacDonald MG, eds. Neonatalogy: Pathophysiology and Management of the Newborn. Philadelphia: J.B. Lippincott, 1994:1000-1028.
35. Clifford Robertson NR. Pneumonia. In: Greenough A, Clifford Robertson NR, Milner AD, eds. Neonatal Respiratory Disorders. New York: Oxford University Press, 1996:393-495.
36. Davis JM, Dickerson B, Metlay L, Penney DP. Differential effects of oxygen and barotrauma on lung injury in neonatal piglet. Pediatr Pulmonol. 1991; 10:157-163.
37. Wilson CB. Lung antimicrobial defenses in the newborn. Semin Respir Med. 1984; 6:149-154.
38. 2-rich environment: The antioxidant enzymes in the developing rabbit lung. Pediatr Res. 1984; 18:240-244.
39. Hudak BB, Egan EA. Impact of lung surfactant therapy on chronic lung diseases in premature infants. Clin Perinatol. 1992; 19:591-602.
40. Davis MG, Coates AL. Maturation of airway mechanics. In: Loughlin GM, Eigen H, eds. Respiratory Disease in Children: Diagnosis and Management. Baltimore: Williams & Wilkins, 1994:1-11.
41. 4 in the genesis of oxygen toxicity in the lung. Am Rev Respir Dis. 1986; 133:805-808.
42. Hageman JR, Babler S, Lee SC, Cobb M, Pachman LM, Smith LJ, Hunt CE. The early involvement of pulmonary prostaglandins in hyperoxic lung injury. Prostaglandins Leukotrienes Med. 1986; 25:105-122.
43. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990, 141:471-501.
44. Ulich TR, Watson LR, Yin SM, Guo K, Wang P, Thang H, Castillo JD. The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and LPS-, IL-1, and TNF-induced inflammatory infiltrate. Am J Pathol. 1991; 138:1485-1496.
45. Huang S, Paulauskis JD, Godleski JJ, Kobzik L. Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation. Am J Pathol. 1992; 141:981-988.
46. Sheppard MN, Harrison NK. New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax. 1992; 47:1064-1074.
47. 1 mRNA expression in acute lung injury. Am J Respir Cell Mol Biol. 1994; 10:148-153.
48. Arnold R, Humbert B, Werchau H, Gallati H, Konig W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology. 1994; 82:126-133.
49. Lohmann-Matthes ML, Steinmuller C, Franke-Ullmann G. Pulmonary macrophages. Eur Respir J. 1994; 7:1678-1689.
50. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol. 1995; 19:371-378.
51. Finkelstein JN, Horowitz S, Sinkin RA, Ryan RM. Cellular and molecular responses to lung injury. Clin Perinatol. 1992; 19:603-620.
52. Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal RG. Antielastases of the human alveolar structures. J Clin Invest. 1981; 68:889-898.
53. Kramps JA, Rudolphus A, Stolk J, Willems LNA, Dijkman JH. Role of antileukoprotease in the human lung. Ann NY Acad Sci. 1991; 624:97-108.
54. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol. 1986; 137:3189-3194.
55. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988; 263: 5380-5384.
56. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL. A role for C - C chemokines in fibrotic lung disease. J Leukoc Biol. 1995; 57:782-787.
57. Northway WH Jr, Rosan C, Porter DY. Pulmonary disease following respiratory therapy of hyaline membrane disease. N Engl J Med. 1967; 76:357-368.
58. Farrel PM, Zimmerman JJ. Bronchopulmonary dysplasia. Curr Opin Pediatr. 1992; 4:410-416.
59. Alpert BE, Allen JL, Schidlow DV. Bronchopulmonary dysplasia. In: Human BC, ed. Pediatric Respiratory Disease: Diagnosis and Treatment. Philadelphia: W.B. Saunders. 1993:440-457.
60. 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. J Clin Invest. 1983; 72:656-666.
61. Ogden BE, Murphy SA, Saunders GC, Pathak D, Johnson JD. Neonatal lung neutrophils and elastase/proteinase imbalance. Am Rev Respir Dis. 1984; 130:817-821.
62. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S. Secretory leukocyte protease inhibitor and inflammation in developing bronchopulmonary dysplasia. J Pediatr. 1994; 125:264-269.
63. Stenmark KR, Eyzaguirre M, Westcott JY, Henson PM, Murphy RC. Potential role of eicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia. Am Rev Respir Dis. 1987; 136:770-772.
64. Kojima T, Sasai M, Kobayashi Y. Increased soluble ICAM-1 in tracheal aspirates of infants with bronchopulmonary dysplasia. Lancet. 1993; 342:1023-1024.
65. Little S, Dean T, Bevin S, Hall M, Ashton M, Church M, Warner J, Shute J. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants. Thorax. 1995; 50:1073-1079.
66. Kotecha S, Chan B, Azam N, Silverman M, Shaw RJ. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chrome lung disease. Arch Dis Child. 1995; 72:F90-F96.
67. Bagchi A, Viscardi RM, Tacia KV, Ensor JR, McCrea KA, Hesday JD. Increased activity interleukin-6 but not tumor necrosis factor-α in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res. 1994; 36:244-252.
68. Groneck P, Götze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics. 1994; 93:712-718.
69. Rozycki HJ. Bronchoalveolar lavage interleukin-1 beta in infants on day 1 of life. South Med J. 1994; 87:991-996.
70. Kotecha S, Azam N, Silverman M, Shaw R. Interleukin-8 and neutrophilia in bronchoalveolar lavage fluid in infants with chronic lung disease of prematurity. (Abstract). Pediatr Res. 1994; 34:340A.
71. McColm J, McIntosh N. Tracheal IL-8 as a predictor of chronic lung disease. (Abstract). Pediatr Res. 1994; 36:28A.
72. Little SA, Devin S, Dean T, Hall M, Ashton M, Church M, Warner JO. The role of IL-8 in pulmonary inflammation during neonatal chronic lung disease. (Abstract). Pediatr Res. 1994; 36: 56A.
73. Munchi UK, Niu JD, Siddiq MM, Parton LA. Tracheal aspirate interleukin-8 (IL-8) elevation followed by interleukin-6 (IL-6) precede the appearance of neutrophils (PML) in preterm neonates who develop bronchopulmonary dysplasia (BPD). (Abstract). Pediatr Res. 1996; 39:232A.
74. Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ. Increase in interleukin (IL)-1β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res. 1996; 40:250-256.
75. Lecart C, Cayabyab R, Kwong K, Buckley S, Minoo P, Warburton D, deLemos R, Jones C. TGF-β bioactivity and its relationship with inflammation in the lungs of preterm newborns with hyaline membrane disease. (Abstract). Pediatr Res. 1996: 39: 337A.
76. Kotecha S, Wangoo A, Silverman M, Shaw RJ. Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before the development of chronic lung disease of prematurity. J Pediatr. 1996; 128:464-469.
77. Jones CA, Cayabyab RG, Kwong KYC, Stotts C, Wong B, Hamdan H, Minoo P, deLemos RA. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: A possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res. 1996; 39:966-975.
78. Spahn JD, Kamada AK. Special considerations in the use of glucocorticoids in children. Pediatr Rev. 1995;16:266-272.
79. Miesfeld RL, Bloom JW. Glucocorticoid receptor structure and function. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma. New York: Marcel Dekker, 1997:3-27.
80. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science. 1995; 270: 286-290.
81. Barnes PJ. Inhaled glucocorticoids in asthma. In: Schleimer RP. Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma. New York: Marcel Dekker, 1997:651-685.
82. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci. 1993; 14:436-441.
83. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985; 75:106-111.
84. Mammel MC, Fiterman C, Coleman M, Boros SJ. Short-term dexamethasone therapy for bronchopulmonary dysplasia: Acute effects and 1-year follow-up. Dev Pharmacol Ther. 1987; 10:1-11.
85. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989; 320:1505-1510.
86. The Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: An international placebo-controlled trial. Pediatrics. 1991; 88:421-427.
87. Groneck P, Reuss D, Götze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr. 1992; 122:938-944.
88. Knoppert DC, Mackanjee HR. Current strategies in the management of bronchopulmonary dysplasia: The role of corticosteroids. Neonatal Netw. 1994; 13:53-60.
89. Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics. 1996; 97:818-821.
90. Williams AF, Jones M. Dexamethasone increases plasma amino acid concentrations in bronchopulmonary dysplasia. Arch Dis Child. 1992; 67:5-9.
91. Ng PC, Brownlee KG, Kelly EJ, Henderson MJ, Smith M, Dear PR. Changes in the plasma aminogram of parenterally fed infants treated with dexamethasone for bronchopulmonary dysplasia. Arch Dis Child. 1992; 67:1193-1195.
92. Co E, Chari G, McCulloch K, Vidyasagar D. Dexamethasone treatment suppresses collagen synthesis in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1993; 16:36-40.
93. Van Goudoever JB, Wattimena JD, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJ. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. J Pediatr. 1994; 124:112-118.
94. Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P. Postnatal development of alveoli: Regulation and evidence for a critical period. J Clin Invest. 1985; 76:1297-1305.
95. Massaro D, Massaro GD, Dexamethasone accelerates postnatal alveolar wall thinning and alters wall composition. Am J Physiol. 1986; 251:R218-R224.
96. Blanco LN, Frank L. Development of gas-exchange surface area in rat lung: The effect of alveolar shape. Am J Respir Crit Care Med. 1994; 149:759-766.
97. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administrated glucocorticoids on rat lung growth. Biol Neonate. 1995; 68:229-245.
98. Yeh TF, Torre AR, Aynebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: A double-blind, controlled study. J Pediatr. 1990; 117:273-282.
99. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996; 98:204-210.
100. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res. 1994; 36:122-128.
101. Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, Bader D, Yurman S, Dolfin T, Kuint J, Milbauer B, Kohelet D, Goldberg M, Armon Y, Davidson S, Sirota L, Amitai M, Zaretsky A, Barak M, Gottfried S. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child. 1996; 74:F33-F37.
102. Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, Newman B, Mimouni FB, Guthrie RD. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995; 126:769-776.
103. Durand M, Mendoza ME, McEvoy C. A randomized study of low-dose dexamethasone therapy in very low birth weight (VLBW) infants at risk for chronic lung disease. (Abstract). Pediatr Res. 1994; 35:1327A.
104. Ali S. Half dose dexamethasone in the treatment of BPD (Abstract). Pediatr Res. 1996; 39:191A.
105. Avent ML, Gal P, Ransom JL. The role of inhaled steroids in the treatment of bronchopulmonary dysplasia. Neonatal Netw. 1994; 13:63-69.
106. Dunn M, Magnani L, Belaiche M. Inhaled corticosteroids in severe bronchopulmonary dysplasia. (Abstract). Pediatr Res. 1989; 25:213A.
107. Pappagallo M, Blondheim O, Brutani V, Abbasi S. Effect of inhaled dexamethasone in ventilator-dependent preterm infants. (Abstract). Pediatr Res. 1990; 27:219A.
108. Pappagallo M, Brutani V, Abbasi S. Nebulized steroid trial in ventilator-dependent preterm infants. (Abstract). Pediatr Res. 1991; 29:327A.
109. Liu EA, Heldt GP. Effects of inhaled beclomethasone in intubated neonates: Phase I trial. (Abstract). Pediatr Res. 1993; 33: 334A.
110. Pokriefka E, Mehdizadeh B, Rabbani A. Inhaled flunisolide in bronchopulmonary dysplasia. (Abstract). Pediatr Res. 1993; 33: 341A.
111. LaForce W, Brudno D. Controlled trial of bronchopulmonary dysplasia by nebulization in oxygen- and ventilator-dependent infants. J Pediatr. 1993; 122:285-288.
112. Gal P, Diaz PR, Ransom JR, Carlos RQ, Thorson DW. Beclomethasone dipropionate for treating premature infants with bronchopulmonary dysplasia. (Letter). J Pediatr. 1993; 123:490-491.
113. Arnon S, Grigg J, Silverman M. Effectiveness of budenoside aerosol in ventilator-dependent preterm babies: A preliminary report. Pediatr Pulmonol. 1996; 21:231-235.
114. Rozycki HJ, Byron PR, Elliot GR, Carrol T, Gutcher GR. Randomized controlled trial of beclomethasone by MDI vs systemic dexamethasone in infants at high risk for BPD. (Abstract). Pediatr Res. 1996; 39:241A.
115. Suchomski SJ, Cummings JJ. Randomized trial inhaled (INH) vs intravenous (IV) steroid in ventilator dependent preterm infants. (Abstract). Pediatr Res. 1996; 39:247A.
116. Kovacs LB, Davis M, Faucher DJ, Papageorgiou AN. Efficacy of early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. (Abstract). Pediatr Res. 1996; 39:337A.
117. Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF, Desfrères L, Llanas B, Guimaraes H, Moriette G, Voyer M, Dehan M, Breart G. Inhaled salbutamol and beclomethasone in prevention of bronchopulmonary dysplasia (BPD): A randomized double-blind study. (Abstract). Am J Respir Crit Care Med. 1996; 153:499A.
118. Gonzales LW, Ballard PL, Ertsey R, Williams MC. Glucocorticoids and thyroid hormones stimulate biochemical and morphological differentiation of human fetal lung in culture. J Clin Endocrinol Metab. 1986; 62:678-691.
119. 3, TRH and their combinations on lung function of ventilated preterm rabbits with and without surfactant treatments. Am Rev Respir Dis. 1987; 136:892-898.
120. Morales WJ, O'Brien WF, Angel JL, Knuppel RA, Sawai S. Fetal lung maturation: The combined use of corticosteroids and thyrotropin-releasing hormone. Obstet Gynecol. 1989; 73:111-116.
121. Ballard RA, Ballard PL, Creasy RK, Padbury J, Polk DH, Bracken M, Moya FR, Gross I, and the TRH Study Group. Respiratory disease in very low-birth weight infants after prenatal thyrotropin-releasing hormone and glucorticoid. Lancet. 1992; 339:510-515.
122. Knight DB, Liggins GC, Wealthail SR. A randomized, controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants. Am J Obstet Gynecol. 1994; 171:11-16.
123. ACTOBAT Study Group. Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease. Lancet. 1995; 345:877-882.
124. Chiswick M. Antenatal TRH. (Comment). Lancet. 1995; 345: 872-873.
125. Hill M, Szefler SJ, Larsen GL. Asthma pathogenesis and the implications for therapy in children. Pediatr Clin North Am. 1992; 39:1205-1224.
126. Watterberg KL, Murphy S, Neonatal Cromolyn Study Group. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia. Pediatrics. 1993; 91:803-806.
127. Stenmark KR, Eyzaguirre M, Remigio L, Seccombe J, Henson PM. Recovery of platelet activating factor and leukotrienes for infant with severe bronchopulmonary dysplasia: Clinical improvement with cromolyn treatment (Abstract). Am Rev Respir Dis. 1985; 131:236A.
128. Yamamoto C, Kojima T, Sasai M, Matsuzaki S, Kobayashi Y. Disodium cromoglycate in the treatment of bronchopulmonary dysplasia. Acta Paediatr Jpn. 1992; 34:589-591.
129. Hudak BB, Egan EA. Impact of lung surfactant therapy on chronic lung diseases in premature infants. Clin Perinatol. 1992; 19:591-602.
130. Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: Effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax. 1988; 43: 354-359.
131. Thomassen MJ, Meeker DP, Antal JM, Connors MJ, Wiedemann HP. Synthetic surfactant (exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am J Respir Cell Mol Biol. 1992; 7:257-260.
132. Matalon S, Holm BA, Baker RR, Whitfield MK, Freeman BA. Characterization of antioxidant activities of pulmonary surfactant mixtures. Biochim Biophys Acta. 1990; 1035:121-127.
133. Gannon DE, He XM, Ward PA, Varani J, Johnson KJ. Time-dependent inhibition of oxygen radical induced lung injury. Inflammation. 1990; 14:509-522.
134. Jacobson JM, Micheal JR, Jafri MH Jr, Gurther GH. Antioxidants and antioxidant enzymes protect against pulmonary oxygen toxicity in the rabbit. J Appl Physiol. 1990; 68:1252-1259.
135. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Friedman A. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr. 1984; 105:781-785.
136. Mikawa K, Nishina K, Maekawa N, Obara H. Attenuation of hyperoxic lung injury in rabbits with superoxide dismutase: Effects on inflammatory mediators. Acta Anaesthesiol Scand. 1995; 39:317-322.
137. Davis JM, Rosenfeld WN, Sanders RJ, Gonenne A. Prophylactic effects of human recombinant superoxide dismutase in neonatal lung injury. J Appl Physiol. 1993; 74:2234-2241.
138. Marzi I, Buhren V, Schuttler A, Trentz O. Value of superoxide dismutase for prevention of multiple organ failure after multiple trauma. J Trauma. 1993; 35:110-119.
139. Davis JM, Rosenfeld WN, Koo HC, Gonenne A. Pharamcologic interactions of exogenous lung surfactant and recombinant human Cu/Zn superoxide dismutase. Pediatr Res. 1994; 35:37-40.
140. Walther FJ, David-Cu R, Lopez SL. Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits. Am J Physiol. 1995; 269:L613-L617.
141. Rosenfeld WN, Davis JM, Parton L, Richter SE, Price A, Plaster E, Kassem N. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics. 1996; 97:811-817.
142. Pearson E, Bose C, Snidow T, Ransom L, Young T, Bose G, Stiles A. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr. 1992; 121:420-427.
143. Robbins ST, Fletcher AB. Early vs delayed vitamin A supplementation in very-low-birth-weight infants. J Parenter Enteral Nut. 1993; 17:220-225.
144. Greenough A. Bronchopulmonary dysplasia: Early diagnosis, prophylaxis, and treatment. Arch Dis Child. 1990; 65:1082-1088.
145. Watts JL, Milner R, Zipursky A, Paes B, Ling E, Gill G, Fletcher B, Rand C. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. Eur Respir J. 1991; 4:188-190.
146. Holtzman RB, Hageman JR, Yogev R. Role of ureaplasma urealyticum in bronchopulmonary dysplasia. J Pediatr. 1989; 114: 1061-1063.
147. Sanchez PJ. Perinatal transmission of ureaplasma urealyticum: Current concepts based on review of the literature. Clin Infect Dis. 1993; 17:S107-S111.
148. Ohlsson A, Wang E, Vearncombe M. Leukocyte counts and colonization with ureaplasma urealyticum in preterm neonates. Clin Infect Dis. 1993; 17:S144-S147.
149. Mulligan MS, Jones ML, Bolanowski MA, Baganoff MP, Deppeler CL, Meyers DM, Ryan US, Ward PA. Inhibition of lung inflammatory reactions in rats by an anti-human interleukin-8 antibody. J Immunol. 1993; 150:5585-5595.
150. Narimanbekov IO, Rozycki HJ. Effect of IL-1 blockade on inflammatory manifestations of acute ventilator-induced lung injury in a rabbit model. Exp Lung Res. 1995; 21:239-254.
151. Rabinovici R, Sofranski MD, Renz JF, Hillegas LM, Esser KM, Vernick J, Feverstein G. Platelet activating factor mediates interleukin-2-induced lung injury in the rat. J Clin Invest. 1992; 89:1669-1673.
152. Murch SH, Costeloe K, Klein NJ, MacDonald TT. Early production of macrophage inflammatory protein-1a occurs in respiratory distress syndrome and is associated with poor outcome. Pediatr Res. 1996; 40:490-497.
153. Bry K, Hallman M, Teramo K, Waffarn F, Lappalainen U. Granulocyte-macrophage colony-stimulating factor in amniotic fluid and in airway specimens of newborn infants. Pediatr Res. 1997; 41:105-109.